ClinicalTrials.gg
CompletedNCT00165646Updated Jul 18, 2011Results posted

A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease

A Phase 3 interventional study of E3810 and E3810 in Non-erosive Gastroesophageal Reflux Disease, sponsored by Eisai Co., Ltd.. Completed at 35 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2011-07-18.

Sponsored by Eisai Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
288
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing rabeprazole in Gastroesophageal Reflux — none open to participants now, none under way, none of them phase 3. Rabeprazole · Gastroesophageal Reflux.

Enrollment
10th of 39
288 · median 100
Started
2004
with 4 others
Phase 3
16 of 40
none open now
Registered
3rd of 40
by date
Lead sponsor
3 of 40
Eisai Co., Ltd.

Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, this one is the 10th largest by enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2004, is one of 16 in phase 3, and was the 3rd registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

None of the 40 studies testing rabeprazole in Gastroesophageal Reflux is open now. The open studies under Gastroesophageal Reflux, anywhere →

About rabeprazole

Rabeprazole: first FDA approval 1999 (ACIPHEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing rabeprazole in Gastroesophageal Reflux as a file.
02

Study summary

To investigate the efficacy and safety of a 4-week treatment of 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)) in patients with non-erosive gastroesophageal reflux disease in a multicenter, randomized, double-blind, comparative study.

03

Conditions studied

  • Non-erosive Gastroesophageal Reflux Disease

Keywords

  • non-erosive gastroesophageal reflux disease
  • NERD
  • proton pump inhibitor
  • rabeprazole
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The patients to be included will be outpatients who meet all of the following criteria. No specific gender is asked.

\<For the observation period>

  1. Patients who have "heartburn" 2 days a week or more for consecutive weeks during 3 weeks prior to pre-observation screening. If a day of screening and a day of starting observation (date of registration) are different, heartburn must continuously be present during the in-between period.
  2. Patients who meet both 1) and 2) below; 1) The symptom is a burning sensation arising from the stomach or the lower chest.
  1. The symptom tends to appear frequently or is aggravated after eating, when bending a body forward, and/or when pressing on the abdomen.

(3) Patients categorized in "grade M" (discoloring type: minimal change) according to the Los Angeles System (2nd Modification) for Classification of Reflux Esophagitis.

(4) Patients who are 20 years old or older at the time of obtaining consent. (5) Patients who are informed of the objective and details of the study and give written consent for study entry.

\<For the treatment period>

  1. Patients who have "heartburn" on 2 days a week or more in 7 days immediately before the treatment period (during the observation period).
  2. Patients with "heartburn diary" that is completely filled out for 7 days until the treatment period (during the observation period). If the observation period is 8 days or longer, those with heartburn diary of which entries are fulfilled 80% or more during the observation period.
  3. Patients with 80% or better drug compliance for antacids during the observation period.

Exclusion criteria

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from the study.

  1. Patients who cannot keep adequate entries of heartburn diary by themselves.
  2. Patients who strongly complain "feeling of heavy stomach" and/or "abdominal bloating."
  3. Patients who have a complication or history of psychiatric or psychosomatic disease (e.g., manic-depressive psychosis, obsessive-compulsive neurosis, or others) or those who are on an antidepressant or anti-anxiety agent (accepted if only for a hypnotic treatment).
  4. Patients who have undergone Helicobacter pylori eradication therapy, and less than 6 months have elapsed from the end of H. pylori eradication therapy to the beginning of the observation period. : The same day 6 months earlier, and the day at the end of 6 months earlier if it is at the end of month.
  5. Patients with open gastric or duodenal ulcer.
  6. Patients with acute gastritis.
  7. Patients with a history of any surgical intervention that affect peptic secretion (e.g., upper gastrointestinal tract resection and/or vagotomy).
  8. Patients with Barrett's esophagus, esophageal stenosis, or pyloric stenosis.
  9. Patients with scleroderma.
  10. Patients with a history or complication of angina pectoris.
  11. Patients who work at night (working for a night-shift).
  12. Patients who received proton pump inhibitors (PPIs) within 3 weeks prior to pre-observation screening
  13. Patients who need NSAIDs (except topical preparations), (except topical preparations), and/or aspirin treatment every day
  14. Patients receiving dialysis therapy
  15. Patients with a serious complication such as cardiovascular disease (e.g., myocardial infarction), hematological disorder (e.g., aplastic anemia), renal disease (e.g., acute or chronic renal failure), hepatic disease (e.g., cirrhosis), or malignant tumor.
  16. Patients with known to antacids or PPIs.
  17. Patients who are pregnant or those with , or those who wish to become pregnant or are lactating during the study period.
  18. Patients receiving another drug or those who received another investigational drug within 6 months prior to pre-observation screening : Registration is allowed on the same day of 6 months earlier, and the day at the end of 6 months earlier if it is at the end of month.
  19. Patients who are judged to be ineligible for the study entry by the investigator or subinvestigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
288 participants (actual)

Study arms

  • Experimental
    1

    Drug: E3810

  • Experimental
    2

    Drug: E3810

  • Placebo comparator
    3

    Drug: Placebo

Interventions

  • DrugE3810

    Drug pages: Rabeprazole · E-3810

    E3810 5mg: once daily orally for 4 weeks

  • DrugE3810

    Drug pages: Rabeprazole · E-3810

    E3810 10mg: once daily orally for 4 weeks

  • DrugPlacebo

    Placebo: once daily orally for 4 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Complete Relief of Heartburn at Final Evaluation

    "Heartburn diary" will be given to each subject and ask him/her to keep the diary every day throughout the study period. The subject will be requested to record the occurrence of heartburn during the daytime and the nighttime in the diary. Primary End Point is the rate of complete disappearance of heartburn. The rate of heartburn do not occur in the past week will be calculated based on the diary. Participants were evaluated at week 4 about episodes of heartburn in the last 7 days

    Time frame: 4 weeks

07

Results

Posted Jun 17, 2011

Participant flow

This study was recruited at 35 centers in Japan during the period of Sep-2004 to Oct-2005.

Participant flow — Overall Study
MilestonePlaceboE3810 5 mgE3810 10 mg
Started9393102
Completed888898
Not completed554
Withdrew: Adverse event111
Withdrew: Lack of efficacy120
Withdrew: Withdrawal by subject021
Withdrew: Physician decision202
Withdrew: Protocol violation100

Outcome measures

PrimaryPercentage of Participants With Complete Relief of Heartburn at Final Evaluation

"Heartburn diary" will be given to each subject and ask him/her to keep the diary every day throughout the study period. The subject will be requested to record the occurrence of heartburn during the daytime and the nighttime in the diary. Primary End Point is the rate of complete disappearance of heartburn. The rate of heartburn do not occur in the past week will be calculated based on the diary. Participants were evaluated at week 4 about episodes of heartburn in the last 7 days

Time frame:
4 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Complete Relief of Heartburn at Final Evaluation
Percentage of participantsPlaceboE3810 5 mgE3810 10 mg
Percentage of Participants With Complete Relief of Heartburn at Final Evaluation20.934.443.6

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/91 (0%)32/91 (35.2%)
E3810 5 mg—1/93 (1.1%)32/93 (34.4%)
E3810 10 mg—0/102 (0%)37/102 (36.3%)
Most frequent serious events
Most frequent serious events
EventPlaceboE3810 5 mgE3810 10 mg
Gastric mucosal lesionGastrointestinal disorders0/911/930/102
Reflux oesophagitisGastrointestinal disorders0/911/930/102
Most frequent other events
Showing 10 of 81
Most frequent other events
EventPlaceboE3810 5 mgE3810 10 mg
NasopharyngitisInfections and infestations9/916/934/102
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders0/915/931/102
DiarrhoeaGastrointestinal disorders4/911/932/102
NauseaGastrointestinal disorders1/911/934/102
Pharyngolaryngeal discomfortRespiratory, thoracic and mediastinal disorders3/911/930/102
Abdominal pain upperGastrointestinal disorders0/913/930/102
RashSkin and subcutaneous tissue disorders0/913/931/102
Abdominal distensionGastrointestinal disorders2/912/933/102
ConstipationGastrointestinal disorders2/910/933/102
Early satietyGeneral disorders2/911/933/102

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboE3810 5 mgE3810 10 mgTotal
Mean49.7 ± 17.046.3 ± 15.346.8 ± 15.747.6 ± 16.0
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboE3810 5 mgE3810 10 mgTotal
Female515551157
Male403850128
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboE3810 5 mgE3810 10 mgTotal
Asian9193101285
Region of Enrollment
Region of Enrollment(participants)PlaceboE3810 5 mgE3810 10 mgTotal
Japan9193101285
08

Study locations

35 sites
  • Aichi-Gun, Aichi-Prefecture 480-1103, Japan
  • Nagoya, Aichi-Prefecture 466-0065, Japan
  • Nagoya, Aichi-Prefecture 467-0001, Japan
  • Chikushino, Fukuoka-Prefecture 818-0024, Japan
  • Chikushino, Fukuoka-Prefecture 818-0067, Japan
  • Fukuoka, Fukuoka-Prefecture 813-0003, Japan
  • Kita-kyushu, Fukuoka-Prefecture 807-1262, Japan
  • Maebashi, Gunma-Prefecture 371-0034, Japan
  • Hiroshima, Hiroshima-Prefecture 730-0052, Japan
  • Hiroshima, Hiroshima-Prefecture 734-0037, Japan
  • Sapporo, Hokkaido-Prefecture 003-0021, Japan
  • Sapporo, Hokkaido-Prefecture 060-0061, Japan
  • Sapporo, Hokkaido-Prefecture 060-0814, Japan
  • Kochi, Kochi-Prefecture 780-0901, Japan
  • Kyoto, Kyoto-Prefecture 602-0000, Japan
  • Kyoto, Kyoto-Prefecture 606-8397, Japan
  • Sandai, Miyagi-Prefecture 980-0872, Japan
  • Sendai, Miyagi-Prefecture 984-0075, Japan
  • Moriguchi, Osaka-Prefecture 570-0021, Japan
  • Osaka, Osaka-Prefecture 530-0012, Japan
  • Osaka, Osaka-Prefecture 536-0002, Japan
  • Osaka, Osaka-Prefecture 545-0051, Japan
  • Saga, Saga-Prefecture 849-0937, Japan
  • Kawaguchi, Saitama-Prefecture 332-0021, Japan
  • Izumo, Shimane-Prefecture 693-0021, Japan
  • Matsue, Shimane-Prefecture 690-0886, Japan
  • Hamamatsu, Shizuoka-Prefecture 431-3125, Japan
  • Shinagawa-ku, Tokyo 140-0011, Japan
  • Shinjuku-ku, Tokyo 162-0052, Japan
  • Sanyoonoda, Yamaguchi-Prefecture 756-0076, Japan
  • Sanyoonoda, Yamaguchi-Prefecture 757-0002, Japan
  • Ube, Yamaguchi-Prefecture 755-0004, Japan
  • Ube, Yamaguchi-Prefecture 755-0046, Japan
  • Ube, Yamaguchi-Prefecture 755-0067, Japan
  • Ube, Yamaguchi-Prefecture 755-0077, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2004, a primary completion of Oct 2005 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 5 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 14, 2005
Start
Sep 2004
Primary completionActual
Oct 2005
CompletionActual
Oct 2005
Results first posted
Jun 17, 2011
Last update
Jul 18, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00165646
Lead sponsor
Eisai Co., Ltd.
First posted
Sep 14, 2005
Start date
Sep 2004
Primary completion
Oct 2005
Completion
Oct 2005
Results posted
Jun 17, 2011
Last update
Jul 18, 2011

Study contacts

Nobuyuki Sugisaki
study director · Eisai Co., Ltd - Development Clinical Research Department. Clinical Research Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rabeprazole · E-3810

Start the discussion